Infectious Disease

It was previously believed that HIV-related brain inflammation may prevent Alzheimer’s disease.

Chimeric antigen receptors, typically studied for cancer immunotherapy, may treat HIV.

Researchers seek to eliminate HIV reservoirs with antiretroviral therapy.

Once-daily dose prevented vaginal and oral HIV transmission in animal models.

Viral suppression may translate to safe sex among couple with an HIV positive individual.

Top news of the day from across the health care landscape.

Researchers seek to induce broadly neutralizing antibodies to block numerous HIV variants.

New class of HIV medications called viral-entry inhibitors protect healthy cells from viral infection.

HIV infection rate among gay and bisexual men remains a problem.

Growing HIV incidence in young individuals could cause epidemic to become worse.

Study sheds light on HIV development.

Care coordination with case management now found to improve HIV viral suppression in hospitalized patients.

Maternal antiretroviral therapy decreases the threat of HIV transmission through breast milk.

Interaction between HIV and the immune system are crucial to eradicating the disease.

CDC finds need for interventions to improve HIV testing rates among men between 15- and 39-years-old.

New analysis may lead to the development of new antiviral HIV drugs.

Antiretroviral therapy may alleviate some cognitive problems among HIV-positive patients.

List prices for Complera and Stribild continue to rise for HIV treatment.

Off-label rilpivirine in combination with emtricitabine and tenofovir may help reduce out-of-pocket spending for patients with HIV.

The CDC recently issued an alert warning health care facilities about Candida auris, an emerging multidrug-resistant yeast.

Infants can quickly produce novel antibodies that protect against HIV.

Antiretroviral therapy use and viral suppression heavily impacted by issues such as poverty and race.

Some injection drug users with HIV and hepatitis C seem to have the same immune problems as the elderly.

Protease inhibitors can frequently lead to cardiovascular disease, diabetes, and obesity.

Engineering bacteria to deliver HIV-1 neutralizing antibodies at the site where the virus enters the body may offer a cost-effective barrier to HIV-1 transmission.